Sanofi SA (0O59)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 73.38 |
|---|---|
| 52-week range | 66.98 – 86.00 |
| Return, 1 month / 3 months | −1.5% / −4.9% |
| Return, 1 year / 3 years | −10.0% / −14.7% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 22.8% |
| Worst drawdown (1 year) | -18.1% |
| Average daily value traded | 69.19M EUR |
| Dividend yield | 5.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sanofi is a pharmaceutical company based in France that researches, develops and makes medicines and vaccines. Its prescription drugs treat conditions in areas such as diabetes, cardiovascular disease, rare diseases and immunology, while its vaccines protect against illnesses including influenza and polio. It also sells consumer healthcare products, such as over-the-counter remedies, and supplies hospitals, pharmacies and doctors in many countries around the world.
Sanofi SA trades under the code 0O59 on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sanofi SA (0O59) trades on the London Exchange in UK. It last closed at EUR 73.38 on 20 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,337 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.0% and over the last three months it fell 4.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 46 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -2.3% | ||
| From 52-week high | -14.1% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.9% | ||
| 6-month return | -4.0% | ||
| 12-month return, skipping the last month | -8.6% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.1% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 69.19M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 65 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.1% |
|---|---|
| 1 month | −1.5% |
| 3 months | −4.9% |
| 6 months | −4.0% |
| 1 year | −10.0% |
| 3 years | −14.7% |
| 5 years | +8.3% |
Signals
| 50-day / 200-day average | 74.33 / 75.09 |
|---|---|
| Golden / death cross (60 days) | Death, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.87 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 4.1200 |
| 12 May 2025 | EUR 3.9200 |
| 13 May 2024 | EUR 3.7600 |
| 30 May 2023 | EUR 3.5600 |
| 6 May 2022 | EUR 3.3300 |
| 5 May 2021 | EUR 3.1826 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.